Exam (elaborations)
Advanced Pharmacology NSG 533 2022 Questions With Answers
- Course
- Institution
Advanced Pharmacology NSG 533 2022 Questions With Answers
[Show more]
Seller
Follow
Kosimaa
Reviews received
Content preview
Advanced Pharmacology NSG 533 2022 Questions With Answers1. EP is a 38-year-old female patient that comes in for diabetes education and management.
She was diagnosed 12 years ago and states lately she is not able to control her diet although
she continues a 1600 calorie diet with appropriate daily carbohydrate intake (per dietitian
prescription) and walks 40 minutes every day of the week. She states compliance with all
medications. She denies any history of hypoglycemia despite being able to identify signs and
symptoms and describe appropriate treatment strategies. PMH: T2DM, HTN, obesity,
depression, s/p thyroidectomy due to thyroid cancer
FmHx: Noncontributory
SHx: ( ) Smoking, alcohol use, past marijuana use while in high school Medications:
Metformin 850 mg tid, glipizide 20 mg bid, lisinopril 20 mg daily, sertraline 100 mg daily,
multivitamin daily
Vitals: BP 128/82 mg Hg; P 72 beats/min; BMI 31 m/kg2
Laboratory test results: Na 134 mEq/L, K 5.4 mEq/L, Cl 106 mEq/L, BUN 16 mg/dL, SCr 0.89
mg/dL, glucose 128 mg/dL; A1C 7.8%
Based on EP's profile above, which of the agents would be able to obtain an A1C goal of less
than 7% and would be appropriate in the patient? Please provide an explanation of
appropriateness or lack thereof.: Exenatide
- Exenatide (Bydureon) once weekly has been able to demonstrate weight loss and decrease A1C%
by 0.7% to 1.2% in clinical trials; however it is contraindicated for EP due to the self-reported
history of thyroid cancer.
Dapagliflozin - Dapagliflozin (Farxiga) is contraindicated in this patient due to hyperkalemia
which could be made worse by this drug. The package insert does not indicate a specific
potassium concentration cut off to no longer use this medication; however, there are better
choices in this patient.
Sitagliptin - Sitagliptin (Januvia) is able to obtain an A1C goal of less than 7% based on clinical
trials and currently the patient does not have any cautionary objective measures to not use this
medication. DPP-IV inhibitors are weight neutral. DPP-IV inhibitors can be used in patients taking
sulfonylureas; however, it may be recommended to reduce or stop the sulfonylurea dose.
,Acarbose - Acarbose (Precose) is not recommended for initial management and is associated with
significant GI side effects. More information would be needed regarding fasting and post-prandial
numbers. In addition, adding acarbose would only lower A1c by 0.8% at best and therefore would
not achieve the desired A1C goal of <7%
2. JR is a 68-year-old African American man with a new diagnosis of T2DM. He was classified
as having prediabetes (at risk for developing diabetes) 5 years before the diagnosis and has a
strong family history of type 2 diabetes. JR's blood pressure was 150/92 mm Hg. His laboratory
results revealed an A1C of 8.1%, normal cholesterol panel, and normal renal/hepatic function
were noted with today's laboratory test results.
Past medical history: Hypertension (diagnosed 4 y ago) Hyperlipidemia (diagnosed 2 y ago)
Pancreatitis (idiopathic) (acute hospitalization 3 y ago) Family history: Type 2 diabetes
Medication: HCTZ 25 mg daily, simvastatin 10 mg daily
Allergies: SMZ/TMP
Vitals: BP: 150/92 mm Hg P: 78 beats/min RR: 12 rpm Waist Circumference:
46 in Weight: 267 lb Height: 5 2 6 3 BMI: 43.1 kg/m 2
Despite improvements in the past six weeks due to lifestyle changes and exercise, drug
therapy is to be started for JR's diabetes. Which drug therapy would be the best for JR to trial?
Discuss your opinion of JR's lipid management.
Discuss your opinion of JR's blood pressure management.: Metformin is the drug of choice
recommended for most patients with diabetes in addition to lifestyle modifications assuming no
contraindications or intolerabilities are present upon evaluation. Metformin has also shown to
provide positive weight neutral/loss effects in obese patients. It is crucial to know the renal status
of patients commencing metformin therapy to limit the risk of lactic acidosis (JR is without
contraindication). Since his entry A1C is >7.5%, dual therapy is indicated.There are several
,potential choices. The second step can be a dipeptidyl peptidase-4 inhibitor, it can be a
glucagon-like peptide-1 (GLP-1) receptor agonist, it can be a TZD, it can be a sulfonylurea agent,
it can be a SGLT2 inhibitor, or it could be basal insulin. Anything next can be tried depending on
what suits the circumstance
DPP4 inhibitors are weight neutral bet relatively benign side effect profile. Sitagliptin has been
associated with case reports of pancreatitis, so this specific agent should be avoided. $$$
GLP-1 analog and has data to support an A1C reduction necessary to gain glycemic control and
may assist with weight loss goals for this patient. New information suggests these agents may
provide benefits in those with ASCVD. JR has a past history of pancreatitis and GLP-1 analogs are
not recommended due to this contraindication
TZDs have data to support an A1C reduction necessary to gain glycemic control, but are
associated with weight gain, negative effects on lipids and increased risk of fracture. Until
recently, TZDs have also been linked to increased CV events and use has fallen out of favor
Sulfonylureas provide excellent A1C lowering, but are also associated with weight gain. They also
have the potential to cause hypoglycemia, so patient education is crucial. Because of his allergies
to "sulfa", use would be contraindicated
SGLT2 inhibitors have data to support an A1C reduction necessary to gain glycemic control. In
addition, they are associated with weight loss and blood pressure lowering. New information
demonstrates these agents may be beneficial in those with ASCVD, heart failure and / or CKD.
They are also associated with dyslipidemias as well. Prior to starting therapy, renal function and
electrolytes would have to be assessed. $$$
Based on the ASCVD recommendations (which are now paralleled by the 2015
ADA recommendations), all patients with type I or II DM ages 40-75 should be on a moderate
intensity statin. If the patients 10 years ASCVD risk is greater than
7.5%, a high intensity statin can be considered. Since all information needed to perform the
estimate is not present, we can assume JR need at least moderate intensity statin. ACCE/ACE
, guidelines still resemble those of ATPIII. Even so, the recommendation is for a statin regardless
of LDL-C in diabetics over 40 with at least 1 risk factor of ASCVD.
Options: atorvastatin 10mg, rosuvastatin 10, simvastatin 20-40, pravastatin 40, lovastatin 40,
fluvastatin 40.
An angiotensin-converting enzyme inhibitor and considered to be a drug of choice for renal
protection in patients with diabetes. ACEi and ARBs have demonstrated a reduction in renal
progression to overt proteinuria. African Americans may not see the maximum effect of blood
pressure lowering with ACEi due to a decreased amount of renin. Combination therapy with a
thiazide would be a reasonable add on
3. A patient with type 1 diabetes reports taking propranolol for hypertension. What concern
does this information present for the provider?: A patient with Type 1 DM is insulin dependent
for glucose control and at high risk for hypo- glycemic episodes. Propanolol causes prolonged
hypoglycemic episodes. Needs to switch to ACE or ARB.
4. A provider teaches a patient who has been diagnosed with hypothyroidism about a new
prescription for levothyroxine. Which statement by the patient indicates a need for further
teaching?
a. "I should not take heartburn medication without consulting my provider first."
b. "I should report insomnia, tremors, and an increased heart rate to my
The benefits of buying summaries with Stuvia:
Guaranteed quality through customer reviews
Stuvia customers have reviewed more than 700,000 summaries. This how you know that you are buying the best documents.
Quick and easy check-out
You can quickly pay through credit card or Stuvia-credit for the summaries. There is no membership needed.
Focus on what matters
Your fellow students write the study notes themselves, which is why the documents are always reliable and up-to-date. This ensures you quickly get to the core!
Frequently asked questions
What do I get when I buy this document?
You get a PDF, available immediately after your purchase. The purchased document is accessible anytime, anywhere and indefinitely through your profile.
Satisfaction guarantee: how does it work?
Our satisfaction guarantee ensures that you always find a study document that suits you well. You fill out a form, and our customer service team takes care of the rest.
Who am I buying these notes from?
Stuvia is a marketplace, so you are not buying this document from us, but from seller Kosimaa. Stuvia facilitates payment to the seller.
Will I be stuck with a subscription?
No, you only buy these notes for $12.49. You're not tied to anything after your purchase.
Can Stuvia be trusted?
4.6 stars on Google & Trustpilot (+1000 reviews)
56326 documents were sold in the last 30 days
Founded in 2010, the go-to place to buy study notes for 14 years now